Molecular modelling studies on d-annulated benzazepinones as VEGF-R2 kinase inhibitors using docking and 3D-QSAR

References

• Peifer C, Bühler S, Hauser D, Kinkel K, Totzke F, Schächtele C, Laufer S. Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors. Eur J Med Chem 2009; 44:1788–1793.
   Google Scholar
• Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46:1116–1119.
   PubMed Web of Science ®Google Scholar
• Gingrich DE, Reddy DR, Iqbal MA, Singh J, Aimone LD, Angeles TS, Albom M, Yang S, Ator MA, Meyer SL, Robinson C, Ruggeri BA, Dionne CA, Vaught JL, Mallamo JP, Hudkins RL. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J Med Chem 2003; 46:5375–5388.
   PubMed Web of Science ®Google Scholar
• Sun L, Tran N, Liang C, Hubbard S, Tang F, Lipson K, Schreck R, Zhou Y, McMahon G, Tang C. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. J Med Chem 2000; 43:2655–2663.
   PubMed Web of Science ®Google Scholar
• Peifer C, Selig R, Kinkel K, Ott D, Totzke F, Schächtele C, Heidenreich R, Röcken M, Schollmeyer D, Laufer S. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. J Med Chem 2008; 51:3814–3824.
   PubMed Web of Science ®Google Scholar
• Baindur N, Chadha N, Brandt BM, Asgari D, Patch RJ, Schalk-Hihi C, Carver TE, Petrounia IP, Baumann CA, Ott H, Manthey C, Springer BA, Player MR. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors. J Med Chem 2005; 48:1717–1720.
   PubMedGoogle Scholar
• Egert-Schmidt AM, Dreher J, Dunkel U, Kohfeld S, Preu L, Weber H, Ehlert JE, Mutschler B, Totzke F, Schächtele C, Kubbutat MH, Baumann K, Kunick C. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation. J Med Chem 2010; 53:2433–2442.
   PubMed Web of Science ®Google Scholar
• Sun L, Tran N, Liang C, Tang F, Rice A, Schreck R, Waltz K, Shawver LK, McMahon G, Tang C. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem 1999; 42:5120–5130.
   PubMed Web of Science ®Google Scholar
• Peifer C, Stoiber T, Unger E, Totzke F, Schächtele C, Marmé D, Brenk R, Klebe G, Schollmeyer D, Dannhardt G. Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione(1) as a highly selective VEGF-R2/3 inhibitor. J Med Chem 2006;49:7549–7553.
   PubMed Web of Science ®Google Scholar
• Sybyl 8.1. St. Louis, US: Tripos Inc.
   Google Scholar
• Song Q-L, Sun P-H, Chen W-M. Exploring 3D-QSAR for ketolide derivatives as antibacterial agents using CoMFA and CoMSIA. Lett Drug Des Discov 2010;7:149–159.
   Web of Science ®Google Scholar
• Politi A, Durdagi S, Moutevelis-Minakakis P, Kokotos G, Papadopoulos MG, Mavromoustakos T. Application of 3D-QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases. Eur J Med Chem 2009; 44:3703–3711.
   PubMed Web of Science ®Google Scholar
• Cichero E, Cesarini S, Fossa P, Spallarossa A, Mosti L. Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses. Eur J Med Chem 2009; 44:2059–2070.
   PubMed Web of Science ®Google Scholar
• Pan X, Tan N, Zeng G, Huang H, Yan H. 3D-QSAR studies on ketoamides of human cathepsin K inhibitors based on two different alignment methods. Eur J Med Chem 2010; 45:667–681.
   PubMed Web of Science ®Google Scholar
• Sun J, Cai S, Yan N, Mei H. Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. Eur J Med Chem 2010; 45:1008–1014.
   PubMed Web of Science ®Google Scholar
• Ravindra GK, Achaiah G, Sastry GN. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Eur J Med Chem 2008; 43:830–838.
   PubMed Web of Science ®Google Scholar
• Teixeira C, Serradji N, Maurel F, Barbault F. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Eur J Med Chem 2009; 44:3524–3532.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang NS, Yoo SE. Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors. Bioorg Med Chem Lett 2008; 18:2479–2490.
   Google Scholar
• Geldenhuys WJ, Nakamura H. 3D-QSAR and docking studies on transforming growth factor (TGF)-beta receptor 1 antagonists. Bioorg Med Chem Lett 2010; 20:1918–1923.
   PubMed Web of Science ®Google Scholar
• Du J, Lei B, Qin J, Liu H, Yao X. Molecular modeling studies of vasclar endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J Mol Grap Model 2009;27:642–654.
   PubMedGoogle Scholar
• Fratev F, Benfenati E. A combination of 3D-QSAR, docking, local-binding energy (LBE) and GRID study of the species differences in the carcinogenicity of benzene derivatives chemicals. J Mol Graph Model 2008; 27:147–160.
   PubMed Web of Science ®Google Scholar
• Hu R, Barbault F, Delamar M, Zhang R. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2009; 17:2400–2409.
   PubMed Web of Science ®Google Scholar
• Gueto C, Torres J, Vivas-Reyes R. CoMFA, LeapFrog and blind docking studies on sulfonanilide derivatives acting as selective aromatase expression regulators. Eur J Med Chem 2009; 44:3445–3451.
   Google Scholar
• Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model 2002; 20:269–276.
   PubMed Web of Science ®Google Scholar
• Basu A, Jasu K, Jayaprakash V, Mishra N, Ojha P, Bhattacharya S. Development of CoMFA and CoMSIA models of cytotoxicity data of anti-HIV-1-phenylamino-1H-imidazole derivatives. Eur J Med Chem 2009; 44:2400–2407.
   PubMed Web of Science ®Google Scholar
• Lu P, Wei X, Zhang R. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase. Eur J Med Chem 2010; 45:3413–3419.
   PubMed Web of Science ®Google Scholar
• Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008;27:302–313.
   Google Scholar